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EMT and MET comprise the processes by which cells transit between epithelial and mesenchymal states, and they
play integral roles in both normal development and cancer metastasis. This article reviews these processes and the
molecular pathways that contribute to them. First, we compare embryogenesis and development with cancer
metastasis. We then discuss the signaling pathways and the differential expression and down-regulation of receptors
in both tumor cells and stromal cells, which play a role in EMT and metastasis. We further delve into the clinical
implications of EMT and MET in several types of tumors, and lastly, we discuss the role of epigenetic events that
regulate EMT/MET processes. We hypothesize that reversible epigenetic events regulate both EMT and MET, and
thus, also regulate the development of different types of metastatic cancers.Review
EMT and MET: an introduction
The epithelial-mesenchymal transition (EMT) was ori-
ginally described in the context of normal cell differenti-
ation during early development [1]. Evolutionarily, the
development of increased differentiation of mesenchy-
mal cells allowed for the organization of highly special-
ized tissues and organ systems in various organisms. As
such, it is not surprising that the molecular pathways
classically associated with EMT, including Snail/Slug,
Twist, Six1, Cripto, TGF-β, and Wnt/β-catenin, are highly
conserved across species [1]. More recently, the role of
adherent EMT in pathogenesis of fibrosis and metastasis
of certain carcinogenic tumors has been described [1-13].
This new paradigm has challenged the field to more ex-
plicitly define EMT. Doing so may help researchers
more accurately assess the relationship between the
normal process of cell differentiation and the analogous
pathological EMT processes. Such EMT processes
occur in both epithelial and non-epithelial cancer, and
while the mechanistic distinction of EMT in these cell
types is worthy of further consideration, it is beyond the
scope of this work. Here, we adopt a broad definition of
EMT that includes molecular changes, decreased cell-
cell recognition and adhesion, and increased potential
for cell motility.* Correspondence: ss1@bu.edu
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(http://creativecommons.org/publicdomain/zerEmbryonic development is a process that involves
growth and differentiation. A significant portion of this
process involves cellular differentiation and tissue for-
mation, and once all major structures are formed,
growth and weight gain take over. The process of a single
cell either differentiating into increasingly specialized cells
or growing and dividing into identical cells is programmed
into its underlying epigenetic controls [14]. The particular
constellation of regulatory changes that enable EMT drive
a normal process of increased differentiation in developing
populations of cells within an organism. However, when
similar epigenetic modifications occur in cancer cells,
these cells become metastatic.
It is important to note that before these cancer cells
are able to metastasize, they must first overcome anoikis,
a form of programed cell death initiated when anchorage-
dependent cells (integrins) detach from the surrounding
ECM [15]. Under normal conditions, when integrins on
the epithelial cell surface come in contact with the ECM,
FAK is activated by phosphorylation, which in turn trig-
gers a phosphorylation cascade ending with the activation
of Akt, thus promoting cell survival. If the integrin should
lose contact with the ECM, the cell survival signals cease,
leaving pro-apoptotic proteins such as Bad uninhibited
and able to initiate cell death. Cancer cells can overcome
anoikis in a variety of ways that are often related to EMT.
For example, a loss of E-cadherin expression and an in-
crease in N-cadherin expression is correlated with anoikis
resistance and increased invasiveness [16]. It has also beenis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
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lead to anoikis resistance.
To summarize, in order to migrate, cancer cells must ac-
tivate genes necessary for differentiation, slow down pro-
liferation events, activate anti-apoptotic mechanisms as
initiating differentiation can induce some apoptotic path-
ways, alter cellular characteristics from epithelial to mes-
enchymal, down-regulate the receptors that aid in cell-to-
cell attachment, up-regulate the cell adhesion molecules
that help in cell movement, degrade cell-to-cell junctions,
and activate proteases at the cell surface in order to cut
through the extracellular matrix. Different populations of
cancer cells possess varying epigenetic patterns that pro-
mote these changes, and each pattern holds different clin-
ical significance. The complexity of EMT and metastasis
lies in the heterogeneity of the population: not all cells will
undergo EMT simultaneously, and not all cells that have
undergone EMT will successfully metastasize. Cancer pro-
genitor cell characteristics, environmental factors, extra-
cellular and intracellular signaling, and epigenetic changes
all influence whether a cell undergoes EMT and
metastasis.
Two hypotheses currently attempt to explain EMT and
metastasis [17]. In the first hypothesis, cancer progenitor
cells present in a tumor do not undergo EMT simultan-
eously, so the cancerous population contains cells at dif-
ferent stages of differentiation. However, these stages are
not fixed. Cancer progenitor cells at any given stage of dif-
ferentiation can undergo EMT to achieve a further stage
of differentiation and develop into an advanced grade of
cancer. Essentially, although these grades are different,
they arise from the same progenitor cell and undergo
differential EMT at different time points. The second hy-
pothesis suggests that some cancer progenitor cells ini-
tially undergo EMT and then metastasize following clonal
expansion. In this instance, a metastatic tumor will share a
signature with the cell that originally underwent EMT,
and thus, every cancer grade should come from a different
progenitor cell. Recent studies in breast cancer have ob-
served that heterogenic metastatic breast cancer tumors
are derived from a few cancer progenitor cells also support
the first hypothesis [18,19]. However, it is still possible for
the heterogeneity of metastatic cancer to be generated by
many cancer progenitor cells differentiating at different
times to produce different cancer grades [20]. The contri-
bution of only a few cancer progenitor cells to metastatic
breast cancer is inconsistent with findings that metastatic
breast cancer cells have high genetic diversity [21]. This
anomaly was recently addressed when it was demon-
strated that heterogeneity in cancer does not evolve from
random genetic changes but rather is orchestrated by an
evolutionary conserved and organized mechanism [22].
This organized mechanism involves the distinct pattern of
epigenetic changes known as EMT [17,18,23].Another important precondition for successful metas-
tasis is the mesenchymal-epithelial transition (MET).
Cancer cells that have undergone EMT and traveled to
other parts of the body must have a mechanism that
allows them to infiltrate other tissues and produce new,
clinically significant tumor sites. To do this, they must
first regain epithelial characteristics so as to anchor
themselves in the surrounding tissue. An example of this
phenomenon is observed in induced pluripotent stem
cells (iPSCs). Recent studies show that producing iPSCs
by increasing the expression of factors that induce MET
also suppresses EMT mediators [24]. This elegant modu-
lation between metastatic and successful implantation in
distant tissues further supports the highly organized,
evolved EMT/MET hypothesis of metastasis.
Mechanisms of EMT
Signaling
Several transcription factors are up-regulated in meta-
static cells that are undergoing EMT, including Snail,
Twist, Zeb, and others. TGF-β plays a large role in acti-
vating Snail, which in turn down-regulates cadherin-16
and HNF-1β, and this process is involved in the epithe-
lial to mesenchymal transition [25]. Because TGF-β also
induces apoptosis, cancer cells must protect themselves
from this cell-death pathway. Interestingly, in addition
to inducing EMT, Snail up-regulates Akt and Bcl-xL,
which inhibit TGF-β-induced apoptosis in cancer cells
[26]. However, in conferring resistance to apoptosis,
Snail has been shown to inhibit cell cycle progression
through the down-regulation of Cyclin D2. When the
cancer cells are going through this differentiation, a
reduction in their cell cycle progression is expected [27].
In a tumor microenvironment, Snail can be activated
through multiple pathways, including HIF1, HIF2, and
Notch in response to hypoxia as well as NF-κB and
TGF-β in response to inflammation [28,29]. IGFR has
been shown to induce EMT through NF-κB and Snail in
mammary epithelial cells. IGFR also up-regulates Zeb in
prostate carcinoma and can activate latent TGF-β1 to
induce EMT [30,31]. It has been proposed that CCN6
(WISP3) can suppress EMT in breast cancer cells by
inhibiting Zeb1 through the modulation of IGF-1 signal-
ing [32]. During EMT, TGF-β can also induce expression
of Cox-2, a gene frequently up-regulated in breast can-
cer. Elevated expression levels of Cox-2 have been asso-
ciated with increased prostaglandin E2 production, and
Cox-2 is believed to be an antagonist of Smad2/Smad3
[33]. In particular, expression levels of HIF-1α, a protein
that plays a central role in the development of aggres-
sive, mesenchymal phenotypes in hypoxic and inflamma-
tory environments, have been shown to induce IL-8,
VEGF, and Twist1 expression, and thus EMT [34]. ERβ1
has been shown to repress EMT by interfering with
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ERE and HRE response elements in the VEGF-A pro-
moter; thus, low levels of ERβ1 result in an EMT.
VEGF-A is thought to be involved in EMT by promoting
nuclear localization of Snail1 [35].
There are also several ways alternative splicing can
play a role in EMT regulation. This was first established
in a study of pancreatic cancer that found specific splice
variants of CD44 in metastasized cancer cells that were
not present in the primary tumor cells [36]. It was later
found that splicing factor ESRP1 in epithelial cells acts
to inhibit the CD44 isoform switching from an epithelial
variant to the mesenchymal variant. During EMT, Snail
inhibits ESRP1, increasing the expression of the CD44
isoform associated with dedifferentiation and invasive-
ness [37]. CD44 is not, by any means, the only example
of alternative splicing affecting EMT [38]. Of interest,
one study found that breast cancer cells undergoing
EMT exhibit a specific alternative splicing signature,
with alternative isoforms of many genes correlating with
alternative invasive phenotypes [39].
Cellular junctions
As the expression of EMT-inducing genes increases, the
cell surface changes dramatically. E-cadherin, a key
marker of the epithelial phenotype, is a transmembrane
protein responsible for anchoring neighboring cells to
one another and forming adherens junctions, with its
cytoplasmic component linked to the actin cytoskeleton
by α- and β-catenin. Loss of this protein is required for
EMT to occur, and it promotes metastasis [40]. Snail,
Zeb, and Twist are well known E-cadherin repressors,
which act by inducing epigenetic silencing at the E-
cadherin promoter in the form of hypermethylation and
histone deacetylation [41]. Expression of N-cadherin and
vimentin, two proteins considered to be markers of a
mesenchymal phenotype and crucial for cellular migra-
tion, are increased during this time as well. Post-
translational control of E-cadherin expression at the cell
surface can be acquired through O-glycosylation of the
protein, which inhibits its transportation to the plasma
membrane [42]. Once at the plasma membrane, E-
cadherin can also be inactivated by proteolytic cleavage
or destabilized by phosphorylation of β-catenin [43]. The
loss of E-cadherin is an integral step in EMT and a key
feature of metastatic cells. Without the tight adherens
junctions keeping tissues together, individual cells are
free to migrate, which is crucial for cancer metastasis.
Receptors
Certain integrins, together with FAK signaling, play a
large role in promoting migration and metastasis in cells
undergoing EMT. FAK is an important tyrosine kinase,
known to phosphorylate β-catenin. Once β-catenin isphosphorylated, it detaches from the E-cadherin com-
plex and localizes to the nucleus where it promotes tran-
scription of genes related to proliferation, migration, and
invasion [43]. Wnt signaling is involved in proliferation.
When Wnt is not present, β-catenin binds conductin,
GSK-3β, and APC in place of E-cadherin. β-catenin’s N-
terminal domain is then phosphorylated by GSK-3β,
leading to degradation of β-catenin through the ubiquitin
proteasome pathway. Wnt activation inhibits GSK-3β and
stabilizes β-catenin, leading to its nuclear localization and
increased expression of oncogenes such as c-myc and
Cyclin D1. Integrin β1 was shown to mediate expression
of FAK in lung cancer cells, with proliferation following
metastasis dependent on β1 and FAK expression levels [44].
A different study demonstrated that nuclear localization
and accumulation of Twist, along with the expression of its
target gene N-cadherin, is mediated by and dependent on
β1 integrin signaling [45]. EGFR has been found to directly
interact with β-catenin as well, causing phosphorylation of
β-catenin and loss of junctions. In metastasis, EGFR can
induce dephosphorylation and subsequent inactivation
of FAK. After metastasis, FAK is re-activated by integrin
signaling during re-adhesion, showing a dynamic regu-
lation of FAK in the processes of EMT and metastasis.
Other integrins have also been linked to the induction
of metastasis. For example, Snail, a known inhibitor of
E-cadherin expression, also promotes expression of the
αvβ3 integrin, which is associated with a pro-invasive
phenotype and activation of TGF-β [46,47].
MMPs
A variety of secreted factors are also important in the
maintenance of EMT and in the promotion of metastasis
[48]. MMPs are capable of cleaving cell-surface proteins
as well as degrading components of the extracellular
matrix, allowing migratory cells to invade neighboring
tissues and break through the basement membrane [49].
E-cadherin is an important substrate of MMPs, as its
cleavage not only helps separate tissues into individual
cells but also induces signaling supportive of EMT.
Cleavage of the E-cadherin ectodomain has been shown
to create a fragment, sE-cad, capable of inducing EMT,
invasion, and proliferation in a paracrine manner via
EGFR signaling [50,51]. Secreted cytokines have been
shown to promote invasive phenotypes. For example,
one study showed that ectopic expression of IL-6 was
associated with E-cadherin repression and increased
expression of Snail, Twist, N-cadherin, and vimentin.
These findings perhaps explain the link between in-
creased IL-6 concentrations and poor survival rates
amongst breast cancer patients [52]. IL-18 has also been
suggested as a marker of metastatic breast cancer and
has been shown to activate MMPs while inducing secretion
of other cytokines [53]. Interestingly, one study showed that
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cardiac smooth muscle cell migration through NF-kB
signaling. It is possible that in the setting of cancer, this
interleukin could promote EMT and metastasis through a
similar pathway [54,55].
Clinical implications of EMT
In Table 1, the various tumor types which have thus far
been most strongly correlated with EMT are presented
with a brief review of known EMT markers. Cancer
types are ordered by the estimated percentage of diag-
nosed patients who have survived 5-year following
cancer metastasis. While this table is by no means ex-
haustive, it helps highlight several interesting trends.
For example, the Snail, Twist, Zeb, and E-cadherin axis as
described above, has thus far been correlated with nearly
every clinically significant tumor type. Furthermore, the
striking commonalities between these distinct tumors re-
veal the profound clinical importance of EMT as a shared,
ubiquitous mechanism that promotes metastasis. Fittingly,
the field of oncology has seen a recent explosion of EMT-
related research for both prognostication and treatment of
metastatic cancers, and to date, numerous classical EMT
markers have been significantly correlated with metastasis.
Moreover, recent works suggest that assessing classical
markers of EMT may help clinicians predict resistance to
chemotherapy, and thus poor prognosis [56].
Another exciting area of research is the use of EMT
markers in the analysis of circulating tumor cells (CTC).
Diagnostically, CTC has been a mainstay of clinical prac-
tice in assessment of metastasis and prognosis. The pres-
ence of CTC in a patient’s blood can be measured using
the AdnaTest, a PCR assay for markers of EMT such as
Twist, Akt, and Pi3k. The test employs a method for
enriching the CTCs in a blood sample using antibodies
conjugated to magnetic beads. Once the tumor cells
have been pulled down, the mRNA can be isolated and
expression of EMT markers determined. The test is re-
ported to be sensitive enough to detect two CTCs in a
5 mL sample of blood [57]. Recent works have indicated
that consideration of CTC EMT status is critical to
achieve a more accurate prognosis. In studies of meta-
static breast cancer, CTC were found to express known
EMT regulators, including TGF-β pathway components
and the FOXC1 transcription factor. These data support
a role for EMT in the blood-borne dissemination of hu-
man breast cancer. Classical markers of EMT, Twist, and
vimentin, have been identified in breast cancer patients
and specifically show elevated expression in patients
with metastatic cancer relative to patients with early-
stage cancer, supporting the hypothesis that EMT con-
trols the metastatic potential of CTCs [58]. Importantly,
other work suggests that EMT-CTCs may be more likely
to evade classical CTC detection by the AdnaTest as aresult of down-regulation of EpCAM. As suggested by
Gorges et al., this may explain why patients with late
metastatic cancers may report low CTC numbers, sug-
gesting the urgent need for a better understanding of
EMT-CTC in prognosis [59,60].Pancreatic cancer
Pancreatic cancer generally has a poor prognosis, in part
because symptoms often do not appear until the cancer
is too advanced for surgical treatment. Pancreatic exo-
crine tumors have an average 5 year survival of up to
14%. Neuroendocrine tumors have a 61% 5-year survival
rate if detected at Stage 1, but these tumors are rarely
detected at this phase [2,89]. Thus, early detection and
inhibition of metastasis remain among the greatest chal-
lenges in the treatment of these tumors. Several genes
related to EMT have been considered with respect to
these clinical challenges. In one in vitro study, Hh in-
hibition with cyclopamine resulted in down-regulation
of Snail and up-regulation of E-cadherin, as well as
a striking reduction of invasive capacity. Combining
gemcitabine and cyclopamine completely abrogated me-
tastasis while also significantly reducing the size of “pri-
mary” tumors. These findings suggest that inhibition of
the Hh pathway is a valid therapeutic strategy for pan-
creatic cancer that particularly targets metastasis
[64,65]. Similarly, Resveratrol, which inhibits pluripotency-
maintaining factors such as Kras (G12D), and EMT
have been indicated in the management of pancreatic
cancer [90,91].Hepatocellular carcinoma
Hepatocellular carcinoma (HCC), which is among the
most deadly forms of cancers worldwide, is the most
common primary liver cancer and is the fastest growing
cause of cancer death in men in the United States [92].
The dominant risk factors are chronic Hepatitis B or
Hepatitis C infection. In addition, cirrhosis can have an
effect on the tumor microenvironment as well as on
tumorigenesis. Cirrhosis can lead to the activation of
stellate cells, which increase production of extracellular
matrix proteins, cytokines, and growth factors, many of
which can alter hepatocyte proliferation and promote
tumorigenesis [93,94]. HCC tends to have a poor prog-
nosis due to late diagnoses and a lack of effective treat-
ment options. While EGFR-targeted therapies have been
successful in some types of cancers, erlotinib and cetuxi-
mab have not been very effective in clinical HCC trials,
particularly in the treatment of mesenchymal HCC cells.
In the case of hepatic carcinomas, Sorafenib, which in-
hibits STAT3 and phosphorylates TGF-β which are both
up-regulated in EMT, is also being studied as a potential
therapeutic agent [67].
Table 1 Major tumor types organized by virulence, clinical significance, and epigenetic markers
Cancer type Survival 5-years after
cancer has metastasized [61]
Survival 5-years after
diagnosis [61]
EMT Markers References
Pancreas 2.3% 6.7% Snail, Twist, Zeb1, Zeb2, E-cadherin, β-catenin Brachyury,
HDAC1,2,3, miR-34, miR-200,
[62-65]
Liver 2.8% 16.6% Snail, Twist, Zeb1, Zeb2, TGF-β, EZH2, HDAC1,2,3, miR-101,
STAT3, SUZ12,
[62,66,67]
Lung 4.0% 16.8% Snail, Zeb1, Zeb2, E-cadherin, vimentin, α-catenin, EZH2,
BMI1, Brachyury, Claudin-1, Cytokeratins, G9a, HDAC1,2,3,
LSD1, miR-34, miR-101, miR-205, Periostin, Slug, SUZ12, TTF-1,
versican, N-cadherin
[62,63,66,68-71]
Bladder 5.5% 77.4% Twist, Zeb1, Zeb2, N-cadherin, EZH2, Fibronectin, LSD1,
miRs-1/133a/218, miR-19a, miRs-30a-3p/133a/199a, miR-34,
miR-99a/100, miR-101, miR-125b, miR-129, miR-145/133a,
miR-200, miR-205, miR-221, N-
[62,66,72]
Renal 12.1% 72.4% TGF-β, BMP-7, Claudin-1, HDAC1,2,3, hepatocyte growth factor,
Klf8, miR-23b, miR-29b, miR-34, miRs-141/200, miR-205,
miR-438-3p,
[62,66,72-74]
Colorectal 12.9% 64.7% Snail, Twist, vimentin, Zeb1, Zeb2, β-catenin, Brachyury,
CD44, E-cadherin, EZH2, FGFR4, Fibronectin, HDAC1,2,3,
LSD1, miR-34, p16INK4a, SIRT1, Slug, SUZ12, SUV39H1,
[62,63,66,72]
Cervical 16.1% 67.9% Snail, Twist, E-cadherin, vimentin, β-catenin, EGFR, [63,66,75,76]
Skin melanoma 16.1% 91.3% TGF-β, MITF, N-cadherin, miR-205 [62,77,78]
Ovarian 27.4% 44.6% Snail, Twist, Zeb1, Zeb2, E-cadherin, CCR7, Claudin-1,
Fibronectin, Klf8, miR-9, miR-34, miR-200, N-cadherin,
Occludin, PTEN, Slug, STK11,
[62,63,66,72,79-82]
Breast 25.0% 89.2% Snail, Zeb1, Zeb2, vimentin, β-catenin, E-cadherin, BMI1,
Brachyury, Claudin, EZH2, HDAC1,2,3, Klf8, LSD1, miR-9 (2);
miR-10b, miR-34, Slug, SUZ12, Twist, versican,
[62,63,66,68,69,83,84]
Prostate 28.0% 98.9% Twist, Zeb1, N-cadherin, APC, Cyclin D2, collagen, decorin,
E47, E-cadherin, ER, EZH2, Fibronectin, GSTP1, HDAC1,2,3,
Let-7a, LSD1, miR-1, miR-7, miR-15a-16 cluster, miR20a,
miR-21, miR-24, miR-32, miR-34a, miR-34c, miR-101, miR-106b,
miR-107, miR125b, miR-143, miR-145, miR-146a, miR-148a,
miR-205, miR-221, miR-222, miR-331-3P, miR-449a, miR-521,
miR-1296, Notch-1, RAR-β2, RASSF1A, versican,
[62,63,72,85-88]
Brain/nervous system 35.6% 33.4% miR-9, Klf8 [62]
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Vimentin positive tumor cells have been detected among
squamous cell carcinomas; although, high epithelial
vimentin has not been correlated with tumor grade.
Squamous cell carcinomas tend to have periostin rich
stroma. Periostin is usually localized to the periphery of
stromal cells surrounding carcinoma cells. Expression of
versican and periostin were frequently accentuated to-
ward the pseudo-basement membrane of the extracellu-
lar matrix around these carcinomas, and high stromal
vimentin is associated with higher grade [71]. Since
EMT plays a large role in the development and spread
of lung cancer, numerous drugs that specifically target
EMT are being developed or are in use in the treatment
of lung cancer. For example, Sorafenib has been show to
increase HAT expression in adenocarcinoma, therefore
positively influencing the epigenetic profile of the cancer
cells [95]. Furthermore, an immunotherapeutic approach
to target a major driver of EMT, the T-box transcription
factor T, also known as brachyury, is currently in Phase I
clinical trial as a potential new therapy for patients with
advanced lung cancer carcinomas [96,97].
Pulmonary adenocarcinoma
Adenocarcinoma is a type of cancerous tumor that
forms from glandular structures [98]. Stromal periostin
protein is associated with versican collagen, and tumor
cell epithelial periostin is associated with both versican
and vimentin. Each of these associations suggests that
cancer cells have undergone EMT and become more
metastatic, but surprisingly, this study did not find a cor-
relation between vimentin up-regulation and morpho-
logical trans-differentiation. However, the authors
observed that the up-regulation of stromal vimentin,
periostin, and versican is associated with higher cancer
grades. As vimentin is the constituent of the cytoskel-
eton network, it is possible that stromal populations go
through certain changes during the induction of EMT.
Similar results were found in breast carcinoma [68,69].
Urothelial carcinoma
Urothelial carcinoma makes up the majority of bladder
cancers and has a high likelihood of returning after
treatment. The most common treatment is surgery if the
carcinoma is detected in an early stage. Urothelial can-
cers are further classified as either superficial or muscle
invasive.
Renal cancer
Via blood filtration, the kidneys are exposed to a dispro-
portionately high concentration of toxins. Thus, perhaps
it is not surprising that renal cancer is one of the 10
most common cancers. EMT has also been observed in
mature epithelial tubular cells and has been linked tothe pathogenesis of renal interstitial fibrosis. Further-
more, in mouse models it has been demonstrated that
the selective blockade of EMT-associated TGF-β, hep-
atocyte growth factor, and BMP-7 expression reduces
fibrotic lesions after obstructive injury [74].
Colorectal cancer
Colorectal cancers tend to start as a small growth in the
inner lining of the colon known as a polyp, ultimately
giving rise to adenocarcinomas. Colorectal cancer is one
of the most common cancers, and yet it is not among
the most lethal cancers as early clinical detection via
routine screenings has dramatically improved overall
mortality [99]. Still, careful study of EMT markers has
revealed additional clinically relevant information. A
clear link has been established between CD44, enhance-
ment of EMT, and colon cancer invasion [100]. Further-
more, FGFR4 has also been shown to play a crucial role
in tumorigenesis, invasion, and survival in colorectal
cancer, and its specific targeting marks a new avenue
of colorectal cancer therapy [101]. Vimentin is highly
expressed in the stroma of colorectal cancer cells com-
pared to healthy cells, but interestingly, not in the cancer
cells themselves. Higher levels of stromal vimentin have
been correlated with poor prognosis of colorectal cancer.
Specifically, since vimentin is expressed in mesenchymal
cells and not epithelial cells, it indicates that EMT has
taken place [102].
Cervical cancer
Perhaps the most significant recent breakthroughs with
respect to cervical cancer have come from the under-
standing that human papilloma virus (HPV) silences
tumor suppressor genes through production of proteins
E6 and E7. However, as worldwide immunization cam-
paigns evolve, cervical cancer persists as a clinical chal-
lenge, and stage IV cervical cancer is still generally
considered untreatable, though chemotherapy is recom-
mended which uses platinum drugs [103]. Several EMT
genes have recently been explored as potential bio-
markers or targets of drug treatment in cervical cancer.
For example, FTS silencing was found to reduce EMT
and cell migration by EGF treatment [104]. Importantly,
Twist2 has been identified as the key Twist isoform
coupling aberrant signals from EMT to senescence, with
significant implications on its potential utility as a bio-
marker of cervical cancer prognosis [75,76].
Melanoma
TGF-β and EMT regulation markers such as MITF have
been shown to play a critical role in melanoma progres-
sion. Furthermore, up-regulation of N-cadherin has been
correlated with an increase in cell migration and inva-
sion. Recent works have demonstrated the causal role of
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vation of PI3K in human melanoma cells, which may
ultimately yield new therapeutic options for these highly
aggressive cancers [77]. Another significant recent insight
has been that the EMT-like switch in phenotype is asso-
ciated with a concomitant change in the expression of
multiple tumor antigens, ultimately allowing cells to
evade T-cell killing. This may have important impli-
cations for future immune therapies such as cancer
vaccination, and careful selection of target antigens may
help circumvent the problem of T-cell evasion by meta-
static melanoma cells [78].
Ovarian cancer
Mutations in the BRCA1 and BRCA2 genes may con-
tribute to development of ovarian cancer. PTEN and
STK11 (a tumor suppressor protein related to EMT)
may also be risk factors. Furthermore, CCR7, which
can be induced in response to hypoxia and is often
constitutively expressed in epithelial ovarian cancer
cells, has been shown to participate in EMT develop-
ment, leading to cell migration and invasion. This sug-
gests that CCR7 may be an effective target for limiting
cell invasion in certain ovarian cancers [80]. Other
recent work has linked hTERT to Slug expression in
norepinephrine-induced ovarian cancer EMT and me-
tastasis. This suggests that these genes may serve as
novel biomarkers and potential therapeutic targets for
ovarian cancer [81,82].
Breast cancer
CTCs that have undergone EMT have been found in pa-
tients with HER2 (+) metastatic breast cancer. CD326
(−) and CD45 (−) cells show an enrichment of circulat-
ing stem cells (CSCs), and have been shown to be corre-
lated with classical markers of EMT such as Snail1 and
Zeb1 [84]. Therefore, assessing EMT-CTCs and CSCs in
HER2 (+) breast cancer patients could be of great prog-
nostic value [84]. Additionally, high levels of CD44 and
low levels of CD24 have been linked to chemotherapy
resistance and cancer relapse in metastatic breast cancer.
Clinically, Lapatinib in combination with conventional
therapy, was demonstrated as a possible therapeutic
strategy for eliminating these cells to decrease recur-
rence and improve long-term survival [105].
Prostate cancer
During prostate cancer progression, as the cells undergo
EMT, the stroma undergoes structural rearrangement in
order to accommodate the tumor cell. Tumor cells can
evade apoptosis by changing their relationship to the
ECM. One marker of a reactive stroma is the presence
of myofibroblasts, which is a cellular intermediate be-
tween fibroblasts and smooth muscle cells [106]. Thesecells secrete fibronectin, collagen, and proteoglycans
such as versican and decorin [107-111]. The reactive
stroma is not only responsible for assisting in EMT but
also contributes to tumor vascularization [112]. Aberrant
glycosylation also impacts such EMT and cell adhesion
[113]. Several patterns of gene silencing have been doc-
umented in advancing prostate cancer. Genes such as
APC, RASSF1A, CCND2, and RAR-β2 are silenced even
in less virulent (low Gleason score) tumors, and loss of
E-cadherin, GSTP1, and ER tend to be silenced in more
aggressive tumors [85-88]. Approximately half of pros-
tate cancers carry TMPRSS2-ERG translocations; how-
ever, the clinical impact of this genomic alteration
remains unclear. Recent studies have suggested that ILK
is a therapeutically targetable mediator of ERG-induced
EMT and transformation in prostate cancer [114].
Glioblastoma
Arising from astrocytes, glioblastoma is the most com-
mon primary and most aggressive CNS tumor subtype.
A particular challenge to treat, the tumors are generally
very heterogeneous, and thus, some cells may respond
to treatment while others may not. Glioblastomas are
highly malignant in part because they reproduce quickly
and have access to many blood vessels, but rarely spread
to distant locations in the body. In glioblastoma multi-
form, EMT has been shown to cooperate with MMP
activity, allowing cells to gain access to lymph vessels.
Preliminary data suggest this new EMT-associated drug
target in combination with stereotactic radiosurgery may
provide potential targets for future treatment [115].
Smoking
Though beyond the scope of this paper, the role of
smoking in the pathogenesis of EMT is also of high clin-
ical significance. Recent works have established direct
connections between cigarette smoke and acute inflam-
matory mechanisms such as NF-kB and EMT [116].
Although the bulk of the evidence for this relationship
has been considered with respect to lung cancers, it is
likely that these mechanisms will be more explicitly
implicated for other tumor types as well. Thus, epide-
miologically, smoking cessation may ultimately prove
among the most important clinical interventions rele-
vant to EMT.
Epigenetics, EMT-MET, and Metastasis
As described in the introduction, embryogenesis is a
process that involves growth and differentiation and is
regulated primarily by epigenetic events. Opportunistic
cancer cells and cancer progenitor cells hijack this
process to their advantage to go through EMT and pos-
sibly the opposite process of MET for successful metasta-
sis. The previous paradigm proposed by many researchers
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mutations and genetic changes does not explain the re-
versible phenomena of EMT and MET, as mutations
and genetic changes are irreversible. For this reason,
Sarkar et al. previously proposed that the initiation of
carcinogenesis and EMT/MET processes should be reg-
ulated by epigenetic mechanisms which are, by default,
reversible [2,17,18,23,117,118]. While mutations and
other genetic alterations can speed up cancer cell
growth at a certain degrees of metastasis, the amount
of EMT defining a particular degree of differentiation
should be controlled by epigenetic changes [17]. These
epigenetic changes involve histone modifications, DNA
methylation, and changes in the expression of miRNA.
Tam and Weinberg also recently proposed that epigen-
etic changes are involved in the stepwise progression of
EMT [119], but they do not describe the changes neces-
sary at different times to produce metastatic cancers of
different grades. As explained by Sarkar et al., these epi-
genetic changes are grade-specific and variable because
they occur at different times, when growth slows down
and differentiation speeds up. Once the differentiation
for the more metastatic form is achieved, growth speeds
up and new mutations incurred at that time may help in
this process of rapid growth. The reverse process takes
place during MET. Thus, epigenetic changes that pro-
mote and enable both EMT and MET are dynamic and
variable, not static. Overall, the involvement of epigen-
etic changes in cancer is well studied, and the invol-
vement of epigenetic changes in cancer initiation are
discussed elsewhere [17,18,23,117,118]. Therefore, in
this review we instead attempt to connect the signifi-
cance of epigenetic changes related to EMT and MET.
As discussed in the signaling section, TGF-β, cadherin,
and integrins play significant roles in EMT. Interestingly,
E-cadherin and integrin α4 are silenced by methylation
during EMT. TGF-β receptors are functional during
EMT as they drive the differentiation process, but these
receptors are silenced by methylation in terminal grade
cancer. This suggests that differentiation is not required
at the terminal grade of metastatic cancer, and therefore,
these receptors are silenced [120]. The epigenetic regula-
tion of TFG-β1 during EMT is supported by a recent
study which demonstrated that HDAC inhibition sup-
presses EMT induced by TGF-β1 in human renal epithe-
lial cells [121]. Sarkar et al. has previously shown that in
addition to increasing acetylation levels in histones,
HDAC inhibitors also demethylate CpG residues by down-
regulating DNMT1 [122-124].
As cancer progenitor cells go through EMT, their
morphology changes, and that requires rearrangement of
the cytoskeleton (Figure 1). Vimentin is an important
constituent of the cytoskeleton, whose expression goes
up in many types of cancer during EMT and in thestromal cells of several cancers, such as non-small-cell
lung cancer and colorectal cancer [70,102]. Additionally,
methylation pattern changes have been observed in the
stromal cells of metastatic breast cancer as far as 4 cm
from the primary tumors [125]. These results suggest
that stromal cells also go through epigenetic changes
that regulate their morphology and function during
EMT. Thus, cancer progenitor cells and stromal cells
may communicate and exchange signaling materials,
possibly through paracrine mechanisms involving cyto-
kines [126], during EMT. While cancer progenitor cells
undergo differentiation and shape changes, stromal cells
close to progenitor cells may also experience morph-
ology change and perhaps differentiation (Figure 1). It is
well known that epigenetic changes occur in cancer pro-
genitor cells, but epigenetic changes also occur in stro-
mal cells [125]. However, this model does not suggest
that the degree of differentiation for all grades of meta-
static cancer happen simultaneously or at a particular
point in time. Rather, this model depicts only the gradual
process of metastasis (Figure 1), which involves gradual
change in epigenetic regulation. As discussed earlier,
such changes are involved in forming different degrees
of cancer metastasis [2,17,18,25,117,118]. Following EMT
and relocation, cancer cells go through MET so as to
attach to the epithelium.
Epigenetic drift, which involves age dependent changes
in genomic methylation patterns, is a new area of interest
that may be relevant to cancer. This phenomenon of epi-
genetic drift may be tissue specific or tissue independent,
and it results in stem cell differentiation processes becom-
ing less flexible with age [127]. Interestingly, cancers and
precursor cancer cells from lesions of advanced metastatic
tumors also demonstrate this type of epigenetic drift, indi-
cating that cancer progenitor cells hijack these age-related
normal changes in epigenetic events in order to promote
EMT for metastasis.
After EMT and once the metastatic cancer cells mi-
grate away from the original tumor, they need to anchor
to distant tissues and organs for successful tumor devel-
opment at the new site. This process requires a reversal
of EMT, or MET, and the re-expression of molecules
that will help those metastatic cancer cells transition to
attach to the new tissue. Although the role of MET in
cancer is a new area of study, recent findings on the
reprogramming of somatic cells to iPSCs reveal that a
key role of BMP signaling is the induction of MET dur-
ing the initiation phase. Interestingly, the miR-205 and
miR-200 family of miRNAs were involved in this
induction process [128]. Down-regulation of miR-34c
has been shown to cause EMT in breast cancer initiating
cells [129]. Another recent study has shown that silen-
cing of TET mediated demethylation of anti-metastatic
miR-200 promotes metastasis in a transgenic mouse
Figure 1 Changes that occur as a tumor cell undergoes EMT and then metastasizes at a secondary location. Epithelial tumor cells are
shown in blue, and stromal cells are shown in green. As a tumor cell undergoes EMT, it begins to lose its epithelial phenotype as shown after
step 2. Loss of cell-to-cell attachment receptors and integrins (shown in purple) also occurs and continues to step 3 and beyond. In addition,
stromal cells near the cancer cell (which is undergoing EMT) are affected and begin undergoing changes (shown as a progression from green to
red cells). Once a cancer cell has completely undergone EMT and travels to a new location, multiple steps (not explicitly shown) involving MET
must occur for the metastatic cancer cell to anchor to the distant site and form a secondary tumor. The stromal cells at the new tumor location
will also undergo change.
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22 [130,131]. Interestingly, it has been observed that
some of miRNA expression is regulated by methylation
[132,133]. Other noncoding RNAs, such as long non-
coding RNAs (lncRNA), have also been shown to be
under epigenetic control and to have a role in regulating
EMT. For example, lncRNA H19, which suppresses
E-cadherin [134], is hypomethylated in bladder cancer,
leading to more metastatic cancer progression [135].
The up-regulation of lncRNA MALAT1 also induces
EMT in bladder cancer [136]. Additionally, several other
cancers are influenced by alterations in lncRNA regula-
tion, which are often induced by Twist and regulate Wnt
downstream [137-139]. These results suggest that epi-
genetics is involved in EMT/MET processes.
After therapies and the apparent remission of the can-
cer, patients often relapse. One of the possible reasons
for relapse is the survival of cancer progenitor cells, and
drug resistant cancer cells at the site of the tumor
[17,18,23,117,118]. Another issue is the presence of
circulating cancer progenitor cells. This is currently a
major field of study, as these cells have the potential to
cause cancer relapse [140]. The presence of these cells in
a patient who is in remission is an indication of possiblecancer relapse. Additionally, as these cells have under-
gone EMT and are in a metastatic state, they need to go
through MET to anchor in distant tissues and form new
tumors. The issue of metastatic cancer progenitor cell
colonization has previously been discussed by Chaffer
and Weinberg [41,48]. Sarkar et al. suggested that this
localization should involve MET [17]. As lung cancer
metastasis is faster than breast and prostate cancer me-
tastasis in a relapse scenario, it is possible that MET is
faster in lung cancer.
Many clinical and research studies suggest that pre-
treatment of cancer patients with epigenetic drugs re-
duces cancer relapse [117,118]. These studies indicate
that inhibition of epigenetic processes may kill cancer
progenitor cells and drug resistant cancer cells, inhibit
EMT, and possibly inhibit MET in circulating cancer
progenitor cells. This topic was discussed in more detail
elsewhere [17].
Conclusion
The metastasis process is different from the initiation
and progression of cancer in that not all of the trans-
formed cells become metastatic. The current paradigm
states that a few of the transformed cancer cells,
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through EMT to produce a metastatic form of cancer.
This is a very complex process, and as described in this
review, it is regulated by diverse mechanisms. As the
metastasis includes both EMT and MET, we believe that
this should be a reversible phenomenon. In the cellular
context, we compare this phenomenon with embryogen-
esis and normal development which are both regulated
by epigenetic changes, such as histone modifications and
DNA methylation and demethylation. One recent study
notes that DNMT1 efficiency is higher in cancer cells as
compared to that in normal cells [141]. This finding
opens a new area of study to determine how the gener-
ation of methylated regions by highly efficient DNMT1
proteins, which regulate enhancer and transcription
factor interactions and gene expression, influences car-
cinogenesis. Additionally, recent computational biology
studies have used enhancer analysis to combine genetic
and epigenetic events in the prediction of gene regula-
tion and expression. They seem to be tissue specific
[142]. In disease conditions including in cancer, the en-
hancer pattern alterations are more at par with epigen-
etic changes rather than mutational and other changes.
The insulated region created by CTCF does not allow
gene expression and most developmentally regulated
genes, and stem cell pluripotency genes are regulated
this way [143]. The insulated region alters during
changes in methylation levels in cancer cells [144]. This
approach will be valuable to test the hypotheses we have
provided in this review and in previous publications
about cancer progenitor cell formation, cancer prog-
ression, EMT/MET, and metastasis [17,18,23,117,118].
Understanding these complex processes will help in de-
veloping improved chemotherapies that could be used to
inhibit metastasis. Many of the anticancer drugs that
inhibit growth and induce tumor cell death are not cap-
able of inhibiting metastasis. Some of the drugs that
show promise in mouse models fail to stop tumor
growth and metastasis in humans. While almost all sig-
naling and genetic events are similar in mice and xeno-
graft tumor models, the role of the stroma as described
in this review may be different in mice and humans and
produce different outcomes. Interestingly, pretreatment
with epigenetic drugs in a combination therapy does re-
duce the relapse of cancer. Elucidation of the exact steps
of EMT will help in the development of improved anti-
metastatic therapies that are useful against circulating
metastatic cancer cells and drug resistant cancer cells.
Abbreviations
EMT: Epithelial-mesenchymal transition; TGF-β: Transforming growth factor
beta; MET: Mesenchymal-epithelial transition; iPSCs: Induced pluripotent stem
cells; Zeb: Zinc finger E-box binding homeobox; HNF-1β: Hepatocyte nuclear
factor 1 homeobox B; HIF: Hypoxia-inducible factors; NF-κB: Nuclear factor
kappa-light-chain-enhancer of activated B cells; IGFR: Insulin-like growth
factor 1 receptor; CCN6: Cysteine-rich secreted protein; WISP3: Wnt1inducible signaling pathway protein 3; IGF-1: Insulin-like growth factor 1;
Cox-2: Cytochrome c oxidase 2; IL: Interleukin; VEGF: Vascular endothelial
growth factor; ER: Estrogen receptor; ERE: Estrogen-responsive element;
HRE: Hormone response element; FAK: Focal adhesion kinase; GSK-
3β: Glycogen synthase kinase 3 beta; APC: Adenomatous polyposis coli;
EGFR: Epidermal growth factor receptor; MMP: Matrix metalloproteinase;
sE-cad: se-cadherin; CTC: Circulating tumor cells; FOXC1: Forkhead box C1;
HER2: Human epidermal growth factor receptor 2; CSC: Cancer stem cells;
EpCAM: Epithelial cellular adhesion molecule; HAT: Histone acetyl transferase;
SIP1: Smad interacting protein 1; Hh: Hedgehog; Kras: V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog; ECM: Extracellular matrix; RASSF1A: Ras
association domain-containing protein 1A; RAR-β2: Retinoid acid receptor
beta 2; GSTP1: Lutathione S-transferase pi 1; FTS: Fused Toes Homolog;
EGF: Epidermal growth factor; BRCA: Breast cancer; PTEN: Phosphatase and
tensin homolog; STK11: Serine/threonine kinase 11; CCR7: Chemokine
receptor 7; hTERT: Telomerase reverse transcriptase; HCC: Hepatocellular
carcinoma; TMZ: Temozolomide; HDAC: Histone deacetylase; DNMT1: DNA
methyltransferase 1; BMP: Bone morphogenic protein; TET: Ten-eleven
translocation methylcytosine dioxygenase.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SS developed the concept. All other authors participated in the manuscript
preparation. All authors read and approved the final manuscript.
Acknowledgments
Work of SS was partially supported by a grant from ACS. SH, GH, ML, ML, and
KL were supported by UROP at BU. SB was supported by MSSRP at BUSM.
Author details
1Cancer Center, Department of Medicine, Boston University School of
Medicine, Boston, MA, USA. 2School of Human Evolution and Social Change,
Arizona State University, Tempe, AZ, USA. 3Harvard Medical School, Boston,
MA, USA.
Received: 2 November 2014 Accepted: 26 January 2015
References
1. Micalizzi D, Farabaugh S, Ford H. Epithelial-mesenchymal transition in
cancer: parallels between normal development and tumor progression.
J Mammary Gland Biol Neoplasia. 2010;15(2):117–34.
2. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, et al.
Genetic and epigenetic aspects of breast cancer progression and therapy.
Anticancer Res. 2014;34(3):1071–7.
3. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer
cells. Science. 2013;342(6159):1234850.
4. Akalay I, Janji B, Hasmim M, Noman MZ, Thiery JP, Mami-Chouaib F, et al.
EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis
through autophagy induction. Autophagy. 2013;9(7):1104–6.
5. Powell D, Blasky A, Britt S, Artinger K. Riding the crest of the wave: parallels
between the neural crest and cancer in epithelial-to-mesenchymal transition
and migration. Wiley Interdiscip Rev Syst Biol Med. 2013;5(4):511–22.
6. Chua K, Sim W, Racine V, Lee S, Goh B, Thiery J. A cell-based small molecule
screening method for identifying inxhibitors of epithelial-mesenchymal
transition in carcinoma. PLoS One. 2012;7(3):e33183.
7. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong W, et al. Mesenchymal
transition and dissemination of cancer cells is driven by myeloid-derived
suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162.
8. Rosenmayr-Templeton L. Industry update: The latest developments in
therapeutic delivery. Ther Deliv. 2010;1(3):369–74.
9. Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, et al.
Phospho-Akt pathway activation and inhibition depends on N-cadherin or
phospho-EGFR expression in invasive human bladder cancer cell lines. Urol
Oncol. 2010;28(2):180–8.
10. Thiery J, Acloque H, Huang R, Nieto M. Epithelial-mesenchymal transitions in
development and disease. Cell. 2009;139(5):871–90.
Heerboth et al. Clinical and Translational Medicine  (2015) 4:6 Page 11 of 1311. Bailey J, Singh P, Hollingsworth M. Cancer metastasis facilitated by
developmental pathways: Sonic hedgehog, Notch, and bone morphogenic
proteins. J Cell Biochem. 2007;102(4):829–39.
12. Thiery J. Epithelial-mesenchymal transitions in development and
pathologies. Curr Opin Cell Biol. 2003;15(6):740–6.
13. Vincent-Salomon A, Thiery J. Host microenvironment in breast cancer
development: epithelial-mesenchymal transition in breast cancer development.
Breast Cancer Res. 2003;5(2):101–6.
14. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian
development. Science. 2001;10(293):1089–93.
15. Kim Y-N, Koo KH, Sung JY, Yun U-J, Kim H. Anoikis Resistance: An Essential
Prerequisite for Tumor Metastasis. Int J Cell Biol. 2012;2012:306879.
16. Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B,
et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic
lobular mammary carcinoma through induction of anoikis resistance and
angiogenesis. Cancer Cell. 2006;10(5):437–49.
17. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer development,
progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14
(10):21087–113.
18. Byler S, Sarkar S. Do epigenetic drug treatments hold the key to killing
cancer progenitor cells? Epigenomics. 2014;6(2):161–5.
19. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M. Prospective
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A.
2003;100(7):3983–8.
20. Campbell L, Polyak K. Breast tumor heterogeneity: cancer stem cells or
clonal evolution. Cell Cycle. 2007;6(19):2332–8.
21. Park S, Gonen M, Kim H, Michor F, Polyak K. Cellular and genetic diversity in
the progression of in situ human breast carcinomas to an invasive
phenotype. J Clin Invest. 2010;120(2):636–44.
22. Meacham C, Morrison S. Tumor heterogeneity and cancer cell plasticity.
Nature. 2013;501:328–37.
23. Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S. Demethylation and
re-expression of epigenetically silenced tumor suppressor genes: sensitization
of cancer cells by combination therapy. Epigenomics. 2013;5(1):87–94.
24. Polo J, Hochedlinger K. When fibroblasts MET iPSCs. Cell Stem Cell. 2010;7:5–6.
25. Boutet A, Esteban M, Maxwell P, Nieto A. Reactivation of Snail genes in
renal fibrosis and carcinogenesis. Cell Cycle. 2007;6(6):638–42.
26. Grille S, Bellacosa A, Upson J, Klein-Szanto A, van Roy F, Lee-Kwon W, et al.
The protein kinase Akt induces epighelial mesenchymal transition and
promotes enhanced motility and invasiveness of squamous cell carcinoma
lines. Cancer Res. 2003;63:2172.
27. Vega S, Morales A, Oscaña O, Valdés F, Fabregat I, Nieto A. Snail blocks the
cell cycle and confers resistance to cell death. Genes Dev. 2004;18:1131–43.
28. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, et al. Hypoxia induces
epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible
factor-1a in hepatocellular carcinoma. BMC Cancer. 2013;13:108.
29. Zhang K, Zhaos J, Liu X, Yan B, Chen D, Gao Y, et al. Activation of NF-kB
upregulates Snail and consequent repression of E-cadherin in
cholangiocarcinoma cell invasion. Hepatogastroenterology. 2011;58(105):1–7.
30. Kim H, Litzenburger B, Cui X, Delgado D, Grabiner B, Lin X, et al. Factor
receptor causes transformation and xenograft growth of immortalized
mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal
transition mediated by NF-kB and Snail. Mol Cell Biol. 2007;27(8):3165–75.
31. Graham T, Zhau H, Odero-Marah V, Osunkoya A, Kimbro S, Tighiouart M,
et al. Insulin-like growth factor-1-dependent up-regulation of ZEB1 drives
epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer
Res. 2008;68:2479.
32. Lorenzatti G, Huang W, Cabanillas A, Kleer C. CCN6 (WISP3) decreases
ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling
in breast cancer. J Cell Sci. 2011;124(10):1752–8.
33. Neil J, Johnson K, Nemenoff R, Schiemann W. Cox-2 inactivates Smad signaling
and enhances EMT stimulated by TGF-B through a PGE2-dependent
mechanisms. Carcinogenesis. 2008;29(11):2227–35.
34. Yang M, Wu M, Chiou S, Chen P, Chang S, Liu C, et al. Direct regulation of
TWIST by HIF-1a promotes metastasis. Nat Cell Biol. 2008;10:295–305.
35. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti C, et al. ERbeta impedes
prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated
snail nuclear localization: implications for Gleason grading. Cancer Cell.
2010;17(4):319–32.
36. Rall C, Rustigi A. CD44 Isoform Expression in Primary and Metastatic
Pancreatic Adenocarcinoma. Cancer Res. 1995;55:1831.37. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al.
CD44 splice isoform switching in human and mouse epithelium is essential
for epithelial-mesenchymal transition and breast cancer progression. J Clin
Invest. 2011;121(3):1064–74.
38. Venables J. Aberrant and Alternative Splicing in Cancer. Cancer Res.
2004;64:7647.
39. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH,
et al. An EMT–Driven Alternative Splicing Program Occurs in Human Breast
Cancer and Modulates Cellular Phenotype. PLoS Genet. 2011;7(8):e1002218.
40. Onder T, Gupta P, Mani S, Yang J, Lander E, Weinberg R. Loss of E-cadherin
promotes metastasis via multiple downstream transcriptional pathways.
Cancer Res. 2008;68:3645.
41. Herranz N, Pasini D, Días V, Francí C, Gutierrez A, Dave N, et al. Polycomb
complex 2 is required for E-cadherin repression by the Snail1 transcription
factor. Mol Cell Biol. 2008;28(15):4772–81.
42. Zhu W, Leber B, Andrews D. Cytoplasmic O-glycosylation prevents cell surface
transport of E-cadherin during apoptosis. EMBO J. 2001;20(21):5999–6007.
43. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion.
Cancer Metastasis Rev. 2009;28:15–33.
44. Shibue T, Weinberg R. Integrin B1-focal adhesion kinase signaling directs
the proliferation of metastatic cancer cells disseminated in the lungs. Proc
Natl Acad Sci U S A. 2009;105(25):10290–5.
45. Alexander N, Tran N, Rekapally H. N-cadherin gene expression in prostate
carcinoma is modulated by integrin-dependent nuclear translocation of
Twist1. Cander Res. 2006;66:3365–9.
46. Mamuya F, Duncan M. aV integrins and TGF-B-induced EMT: a circle of regu-
lation. J Cell Mol Med. 2012;16(3):445–55.
47. Haraguchi M, Okubo T, Miyashita Y, Miyamoto Y, Hayashi M, Crotti T, et al.
Snail regulates cell-matrix adhesion by regulation of the expression of integrins
and basement membrane proteins. J Biol Chem. 2008;283(35):23514–23.
48. Chaffer C, Weinberg R. A perspective on cancer cell metastasis. Science.
2011;331(6024):1559–64.
49. Brinckerhoff C, Matrisian L. Matrix metalloproteinases: a tail of a frog that
became a prince. Nat Rev Mol Cell Biol. 2002;3:207–14.
50. David J, Rajasekaran A. Dishonorable discharge: the oncogenic roles of
cleaved E-cadherin fragments. Cancer Res. 2012;72:2917.
51. Noe V, Fingleton B, Jacobs K, Crawford H, Vermeulen S, Steelant W, et al.
Release of an invasion promoter E-cadherin fragment by matrilysin and
stromelysin-1. J Cell Sci. 2001;114:111–8.
52. Sullivan N, Sasser A, Axel A, Vesuna F, Raman V, Ramierz N, et al. Interleukin-6
induces and epithelial-mesenchymal transition phenotype in human breast
cancer cells. Oncogene. 2009;28:2940–7.
53. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression.
Cell Mol Immunol. 2007;4(5):329.
54. Chandrasekar B, Mummidi S, Mahimainathan L, Patel D, Bailey S, Imam S,
et al. Dependent on NF-kB and AP-1 mediated matrix metalloproteinase-9
expression and IS inhibited by atorvastatin. J Biol Chem. 2006;281:15099–109.
55. Wang M, Markel T, Meldrum D. Interleukin 18 in the heart. Shock. 2008;30
(1):3–10.
56. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell
and epithelial-mesenchymal transition markers are frequently overexpressed
in circulating tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 2009;11:R46.
57. Andreopoulou E, Yang L, Rangel K, Reuben J, Hsu L, Krishnamurthy S, et al.
Comparison of assay methods for dectection of circulating tumor cells in
metastatic breast cancer: AdnaGen Adna Test Breast Cancer Select/Detect
versus Veridex Cell Search System. Int J Cancer. 2011;130(7):1590–7.
58. Yu M, Bardia A, Wittner BS, Stott SL, Malgorzata ES, Ting DT, et al. Circulating
breast tumor cells exhibit dynamic changes in epithelial and mesenchymal
composition. Science. 2013;339:580–4.
59. Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, et al.
Circulating tumour cells escape from EpCAM-based detection due to
epithelial-to-mesenchymal transition. BMC Cancer. 2012;12:178.
60. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al.
Epithelial-mesenchymal transition and stemness features in circulating
tumor cells from breast cancer patients. Breast Cancer Res Treat.
2011;130:449–55.
61. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat
Database: Incidence. SEER 18 Regs Research
Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub, Vintage
2009 Pops (2000–2009) <Katrina/Rita Population Adjustment>.
Heerboth et al. Clinical and Translational Medicine  (2015) 4:6 Page 12 of 1362. Craene BD, Berx G. Regulatory networks defining EMT during cancer initiation
and progression. Nat Rev Cancer. 2013;13(2):97–110.
63. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of
epithelial-mesenchymal transition. Clin Transl Med. 2014;3:17.
64. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al.
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and
metastases: a new paradigm for combination therapy in solid cancers.
Cancer Res. 2007;67:2187–96.
65. Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, et al. An orally
bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor
initiation and metastasis in pancreatic cancer. Mol Cancer Ther. 2008;7:2725–35.
66. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al.
Epithelial–mesenchymal transition in cancer development and its clinical
significance. Cancer Sci. 2010;101:293–9.
67. Chen YL, Lv J, Ye XL, Sun MY, Xu Q, Liu CH, et al. Sorafenib inhibits transforming
growth factor beta1-mediated epithelial-mesenchymal transition and apoptosis
in mouse heptatocytes. Hepatology. 2011;53:1708–18.
68. Shao R, Bao S, Bai X, Blanchette C, Anderson R, Dang T, et al. Acquired
expression of periostin by human breast cancers promotes tumor
angiogenesis through up-regulation of vascular endothelial growth factor
receptor 2 expression. Mol Cell Biol. 2004;24(9):2993–4003.
69. Sasaki H, Yu C, Dai M, Tam C, Loda M, Auclair D, et al. Elevated serum
periostin levels in patients with bone metastases from breast but not lung
cancer. Breast Cancer Res Treat. 2003;77(3):245–52.
70. Li M, Li C, Li D, Xie Y, Shi J, Li G, et al. Periostin, a stroma-associated protein,
correlates with tumor invasiveness and progression in nasopharyngeal
carcinoma. Clin Exp Metastasis. 2012;29(8):865–77.
71. Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E,
et al. Versican in nonsmall cell lung cancer: relation to hyaluronan,
clinicopathologic factors, and prognosis. Hum Pathol. 2005;36(1):44–50.
72. Catto JWF, Alcaraz A, Bjartell AS, De Vere WR, Evans CP, Fussel S, et al.
MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. Eur
Urol. 2011;59(5):671–81.
73. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis
initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.
74. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic
significance, molecular mechanism, and therapeutic intervention. J Am Soc
Nephrol. 2004;15:1–12.
75. Wang T, Li Y, Wang W, Tuerhanjiang A, Wu Z, Yang R, et al. Twist2, the key
Twist isoform related to prognosis, promotes invasion of cervical cancer by
inducing epithelial-mesenchymal transition and blocking senescence. Hum
Pathol. 2014;45(9):1839–46.
76. Lee M, Chou C, Tang M, Shen M. Epithelial-mesenchymal transition in
cervical cancer: correlation with tumor progression, epidermal growth factor
receptor overexpression, and snail up-regulation. Clin Cancer Res. 2008;14
(15):4743–50.
77. Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3K
signalling is required for a TGFβ-induced epithelial-mesenchymal-like transi-
tion (EMT-like) in human melanoma cells. Exp Dermatol. 2014, doi:10.1111/
exd.12580.
78. Woods K, Pasam A, Jayachandran A, Andrews MC, Cebon J. Effects of
epithelial to mesenchymal transition on T cell targeting of melanoma cells.
Front Oncol. 2014;4:367.
79. King M, Marks J, Mandell J, The New York Breast Cancer Study Group. Breast
and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Science. 2003;302(5645):643–6.
80. Cheng S, Han L, Guo J, Yang Q, Zhou J, Yang X. The essential roles of CCR7
in epithelial-to-mesenchymal transition induced by hypoxia in epithelial
ovarian carcinomas. Tumour Biol. 2014;35(12):12293–8.
81. Zhou XM, Zhang H, Han X. Role of epithelial to mesenchymal transition
proteins in gynecological cancers: pathological and therapeutic
perspectives. Tumour Biol. 2014;35(10):9523–30.
82. Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, Rha SY, et al. hTERT mediates
norepinephrine-induced Slug expression and ovarian cancer aggressiveness.
Oncogene. 2014 Aug 25;0. doi: 10.1038/onc.2014.270. [Epub ahead of print]
PubMed PMID: 25151968
83. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis.
Cancer. 1997;80:1529–37.
84. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, et al. Epithelial-
mesenchymal transition and stem cell markers in patients with HER2-
positive metastatic breast cancer. Mol Cancer Ther. 2012;11:2526–34.85. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, et al.
High promoter methylation levels of APC predict poor prognosis in sextant
biopsies from prostate cancer patients. Clin Cancer Res. 2007;13:6122–9.
86. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al.
Correlation of E-cadherin expression with differentiation grade and histo-
logical type in breast carcinoma. Am J Pathol. 1993;142:987–93.
87. Jerónimo C, Henrique R, Hoque M, Mambo E, Ribeiro F, Varzim G, et al. A
quantitative promoter methylation profile of prostate cancer. Clin Cancer
Res. 2004;10:8472.
88. Li L, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent Methylation of
estrogen receptor in prostate cancer: correlation with tumor progression.
Cancer Res. 2000;60:702–6.
89. Bilimoria K, Bentrem D, Ko C, Ritchey J, Stewart A, Winchester D, et al.
Validation of the 6th edition AJCC pancreatic cancer staging system.
Cancer. 2007;110(4):738–44.
90. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, et al. Resveratrol
inhibits pancreatic cancer stem cell characteristics in human and KrasG12D
transgenic mice by inhibiting pluripotency maintaining factors and
epithelial-mesenchymal transition. PLoS One. 2011;6:e16530.
91. Maier HJ, Wirth T, Beug H. Epithelial-Mesenchymal Transition in Pancreatic
Carcinoma Cancers (Basel). Cancers. 2010;2:2058–83.
92. El-Serag H, Rudolph KL. Hepatoceullar carcinoma: epidemiology and
molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
93. Giannelli G, Bergamini E, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with
transforming growth factor-beta 1 induces epithelial to mesenchymal transition
in hepatocellular carcinoma. Gastroenterology. 2005;129:1375–83.
94. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.
95. Zhang J, Chen Y, Ji G, Fang W, Gao Z, Liu Y, et al. Sorafenib inhibits
epithelial-mesenchymal transition through an epigenetic-based mechanism
in human lung epithelial cells. PLOS. 2013;8(5):e64954.
96. Palena C, Fernando RI, Hamilton DH. An immunotherapeutic intervention
against tumor progression: targeting a driver of the epithelial-to-mesenchymal
transition. Oncoimmunology. 2014;3:e27220.
97. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, et al.
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate
sensitivity to epidermal growth factor receptor inhibition in human hepatoma
cells. Cancer Res. 2008;68:2391–9.
98. Sihoe A, Yim A. Lung cancer staging. J Surg Res. 2004;117(1):92–106.
99. Clintron J, Pearl R. Colorectal cancer and peritoneal carcinomatosis. Semin
Surg Oncol. 1996;12(4):267–78.
100. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, et al. CD44 enhances
the epithelial-mesenchymal transition in association with colon cancer
invasion. Int J Oncol. 2012;41:211–8.
101. Paláez-García A, Barderas R, Torres S, Hernández-Varas P, Teixidó J, Bonilla F,
et al. FGFR4 role in epithelial-mesenchymal transition and its therapeutic
value in colorectal cancer. PLoS One. 2013;8:e63695.
102. Ngan CY, Yamamoto H, Seshimo I, Tsujino T, Man-I M, Ikeda I, et al.
Quantitative evaluation of vimentin expression in tumor stroma of colorectal
cancer. Br J Cancer. 2007;96:986–92.
103. Brown S, Brown E, Walker I. The present and future role of photodynamic
therapy in cancer treatment. Lancet Oncol. 2004;5(8):497–508.
104. Muthusami S, Prabakaran D, Yu J, Park W. EGF-induced expression of Fused
Toes Homolog (FTS) facilitates epithelial-mesenchymal transition and promotes
cell migration in ME180 cervical cancer cells. Cancer Lett. 2014;351(2):252–9.
105. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, et al. Intrinsic
resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer
Inst. 2008;100:672–9.
106. Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR, Majno G. Granulation tissue as
a contractile organ. A study of structure and function. J Exp Med.
1972;135:719–34.
107. Sonmez H, Suer S, Karaarslan I, Baloglu H, Kokoglu E. Tissue fibronectin
levels of human prostatic cancer, as a tumor marker. Cancer Biochem
Biophys. 1995;15:107–10.
108. Roberts DD. Regulation of tumor growth and metastasis by
thrombospondin-1. FASEB J. 1996;10:1183–91.
109. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, et al.
Elevated levels of versican but not decorin predict disease progression in
early-stage prostate cancer. Clin Cancer Res. 1998;4:963–71.
110. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD,
et al. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia,
and carcinoma. Hum Pathol. 1993;24:982–9.
Heerboth et al. Clinical and Translational Medicine  (2015) 4:6 Page 13 of 13111. Albrecht M, Renneberg H, Wennemuth G, Möschler O, Janssen M, Aumüller G,
et al. Fibronectin in human prostatic cells in vivo and in vitro: expression,
distribution, and pathological significance. Histochem Cell Biol. 1999;112:51–61.
112. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in
the tumor microenvironment: is there are role in prostate cancer
metastasis? Cancer Res. 2005;65:11230–5.
113. Lange T, Samatov TR, Tonevitsky AG, Schumacher U. Importance of
altered glycoprotein-bound N- and O-glycans for epithelial-to-
mesenchymal transition and adhesion of cancer cells. Carbohydr Res.
2014;389:39–45.
114. Becker-Sanos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-
Dimas M, et al. Integrin-linked kinase as a target for ERG-mediated inva-
sive properties in prostate cancer models. Carcinogenesis.
2012;33:2558–67.
115. Greenspoon JN et al. Fractionated stereotactic radiosurgery with concurrent
temozolomide chemotherapy for locally recurrent glioblastoma multiforme:
a prospective cohort study. Oncol Targets Ther. 2014;7:485–90.
116. Zhao Y, Xu Y, Li Y, Xu W, Luo F, Wang B, et al. NF-κB-mediated inflammation
leading to EMT via miR-200c is involved in cell transformation induced by
cigarette smoke extract. Toxicol Sci. 2013;135(2):265–76.
117. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al.
Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–92.
118. Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S, Sarkar S. Use of
epigenetic drugs in disease: an overview. Genet Epigenet. 2014;6:9–19.
119. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity
in cancer. Nat Med. 2013;19:1438–49.
120. Miettinen P, Ebner R, Lopez A, Derynck R. TGF-β induced transdifferentiation
of mammary epithelial cells to mesenchymal cells: involvement of type I
receptors. J Cell Bol. 1994;127:2021–36.
121. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone
deacetylases activity suppresses epithelial-to-mesenchymal transition
induced by TGF- β1 in human renal epithelial cells. J Am Soc Nephrol.
2005;18(1):158–65.
122. Mataga M, Rosenthal S, Heerboth S, Devalapalli A, Kokolus S, Evans L, et al.
Anti-breast cancer effects of histone deacetylases inhibitors and calpain
inhibitor. Anticancer Res. 2012;32(7):2525–9.
123. Sarkar S, Abujamra A, Loew J, Forman L, Perrine S, Faller D. Histone
deacetylases inhibitors reverse CpG methylation by regulating DNMT1
through ERK signaling. Anticancer Res. 2011;31(9):2723–32.
124. Sarkar S, Longacre M, Tatur N, Heerboth S, and Lapinska K: Histone
deacetylases (HDACs): function, mechanism, and inhibition. Encyclopedia of
Analytical Chemistry 2014, doi: 10.1002/9780470027318.a9365.
125. Yan P, Venkataramu C, Ibrahim A, Liu J, Shen R, Diaz N, et al. Mapping
geographic zones of cancer risk with epigenetic biomarkers in normal
breast tissue. Clin Cancer Res. 2006;12(22):6626–36.
126. Muller A, Homey B, Soto H, Ge N, Cantron D, Buchanan M, et al.
Involvement of chemokine receptors in breast cancer metastasis. Nature.
2001;410:50–6.
127. Teschendorff A, West J, Beck S. Age-associated epigenetic drift: implications,
and a case of epigenetic thrift. Hum Mol Genet. 2013;22:R7–15.
128. Samavarchi-Tehrani P, Golipour A, David L, Sung H, Beyer TA, Datti A, et al.
Functional genomics reveals a BMP-driven mesenchymal-to-epithelial
transition in the initiation of somatic cell reprogramming. Cell Stem Cell.
2010;7:64–77.
129. Yu F, Jiao Y, Zhu Y, Wang Y, Zhu J, Cui X, et al. MicroRNA 34c gene
down-regulation via DNA methylation promotes self-renewal and
epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol
Chem. 2012;287:465–73.
130. Song S, Poliseno L, Song M, Ala U, Webster K, Beringer G, et al.
MicroRNA-antagonism regulates breast cancer stemness and metastasis via
TET-family-dependent chromatin remodeling. Cell. 2013;154(2):311–24.
131. Song S, Ito K, Ala U, Kats L, Webster K, Sun S, et al. The oncogenic microRNA
miR-22 targets the TET2 tumor suppressor to promote hepatopoietic stem cell
self-renewal and transformation. Cell Stem Cell. 2013;13(7):87–101.
132. Lv L, Deng H, Zhang C, Liu X, Liu Q, Zhang D, et al. The DNA
methylation-regulated miR-193a-3p dictates the multichemoresistance of
bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death
Dis. 2014;5:e1402.
133. Cheung H, Davis A, Lee T, Pang A, Nagrani S, Rennert O, et al. Methylation
of an intronic region regulates miR-199a in testicular tumor malignancy.
Oncogene. 2011;30(31):3404–15.134. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19
increases bladder cancer metastasis by associating with EZH2 and inhibiting
E-cadherin expression. Cancer Lett. 2013;333(2):213–21.
135. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA. Large scale mapping of
methylcytosines in CTCF-binding sites in the human H19 promoter and
aberrant hypomethylation in human bladder cancer. Hum Mol Genet.
2001;10(23):2619–26.
136. Ying L, Chen Q, Wang Y, Zhou Z, Huanga Y, Qiu F. Show Affiliations
Upregulated MALAT-1 contributes to bladder cancer cell migration by
inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012;8:2289–94.
137. Sun T, Wong N. Transforming growth factor-β–induced long noncoding
RNA promotes liver cancer metastasis via RNA–RNA crosstalk. Hepatology.
2015, doi: 10.1002/hep.27599.
138. Sun M, Liu X-H, Lu K-H, Nie F-Q, Xia R, Kong R, et al. EZH2-mediated epigenetic
suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell
proliferation and metastasis by affecting the epithelial–mesenchymal
transition. Cell Death Dis. 2014;5:e1298.
139. Hu P, Yang J, Hou Y, Zhang H, Zeng Z, Zhao L, et al. LncRNA expression
signatures of twist-induced epithelial-to-mesenchymal transition in MCF10A
cells. Cell Signal. 2014;26(1):83–93.
140. Cristofanili M, Budd T, Ellis M, Stopeck A, Matera J, Miller C, et al. Circulating
tumor cells, disease progression, and survival in breast cancer. N Engl J
Med. 2004;351:781–91.
141. Samorodnitsky E, Ghosh E, Mazumder S, Sarkar S. Methylation by DNMT1 is
more Efficient in Chronic Lymphocytic Leukemia Cells than in Normal Cells.
J Proteomics Bioinform. 2014;S10:004.
142. Kheradpour P, Ernst J, Melnikov A, Rogov P, Wang L, Zhang X, et al. Systematic
dissection of regulatory motifs in 2000 predicted human enhancers using a
massively parallel reporter assay. Genome Res. 2013;23(5):800–11.
143. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, et al. Control of
Cell Identity Genes Occurs in Insulated Neighborhoods in Mammalian
Chromosomes. Cell. 2014;159:374–87.
144. Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. Reconfiguration of
nucleosome-depleted regions at distal regulatory elements accompanies
DNA methylation of enhancers and insulators in cancer. Genome Res.
2014;24:1421–32.Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
